Literature DB >> 26969667

Comprehensive profiling of EBV gene expression in nasopharyngeal carcinoma through paired-end transcriptome sequencing.

Lijuan Hu1,2,3, Zhirui Lin1,2, Yanheng Wu1, Juqin Dong1,2, Bo Zhao4, Yanbing Cheng5, Peiyu Huang1,6, Lihua Xu1,7, Tianliang Xia1,2, Dan Xiong1,2, Hongbo Wang1,2, Manzhi Li1,2, Ling Guo1,6, Elliott Kieff4, Yixin Zeng1,2, Qian Zhong8,9, Musheng Zeng10,11.   

Abstract

The latent expression pattern of Epstein-Barr Virus (EBV) genes in nasopharyngeal carcinoma (NPC) has been extensively investigated, and the expression of several lytic genes in NPC has been reported. However, comprehensive information through EBV transcriptome analysis in NPC is limited. We performed paired-end RNA-seq to systematically and comprehensively characterize the expression of EBV genes in NPC tissue and C666-1 NPC cell line, which consistently carries EBV. In addition to the transcripts restricted to type II latency infection, the type III latency EBNA3s genes and a substantial number of lytic genes, such as BZLF1, BRLF1, and BMRF1, were detected through RNA-seq and were further verified in C666-1 cells and NPC tissue through realtime PCR.We also performed clustering analysis to classify NPC patient groups in terms of EBV gene expression, which presented two subtypes of NPC samples. Results revealed interesting patterns of EBV gene expression in NPC patients. This clustering was correlated with many signaling pathways, such as those related to heterotrimeric G-protein signaling, inflammation mediated by chemokine and cytokine signaling, ribosomes, protein metabolism, influenza infection, and ECM-receptor interaction. Our combined findings suggested that the expression of EBV genes in NPC is restricted not only to type II latency genes but also to type III latency and lytic genes. This study provided further insights into the potential role of EBV in the development of NPC.

Entities:  

Keywords:  Epstein-Barr virus; latency genes; lytic genes; nasopharyngeal carcinoma; paired-end transcriptome sequencing

Mesh:

Substances:

Year:  2016        PMID: 26969667     DOI: 10.1007/s11684-016-0436-0

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  41 in total

1.  Advancing RNA-Seq analysis.

Authors:  Brian J Haas; Michael C Zody
Journal:  Nat Biotechnol       Date:  2010-05       Impact factor: 54.908

2.  Power of deep sequencing and agilent microarray for gene expression profiling study.

Authors:  Lin Feng; Hang Liu; Yu Liu; Zhike Lu; Guangwu Guo; Suping Guo; Hongwei Zheng; Yanning Gao; Shujun Cheng; Jian Wang; Kaitai Zhang; Yong Zhang
Journal:  Mol Biotechnol       Date:  2010-06       Impact factor: 2.695

3.  Expression of Epstein-Barr virus lytic gene BRLF1 in nasopharyngeal carcinoma: potential use in diagnosis.

Authors:  Ping Feng; Ee Chee Ren; Dingxiang Liu; Soh Ha Chan; Huaizhong Hu
Journal:  J Gen Virol       Date:  2000-10       Impact factor: 3.891

4.  Epstein-Barr virus encoded BALF1 gene is transcribed in Burkitt's lymphoma cell lines and in nasopharyngeal carcinoma's biopsies.

Authors:  G Cabras; G Decaussin; Yué Zeng; D Djennaoui; H Melouli; P Broully; A M Bouguermouh; T Ooka
Journal:  J Clin Virol       Date:  2005-09       Impact factor: 3.168

5.  Identification of novel Epstein-Barr virus microRNA genes from nasopharyngeal carcinomas.

Authors:  Jia Yun Zhu; Thorsten Pfuhl; Natalie Motsch; Stephanie Barth; John Nicholls; Friedrich Grässer; Gunter Meister
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

6.  Growth-promoting properties of Epstein-Barr virus EBER-1 RNA correlate with ribosomal protein L22 binding.

Authors:  Jennifer L Houmani; Christopher I Davis; Ingrid K Ruf
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

7.  Characterization of Epstein-Barr virus miRNAome in nasopharyngeal carcinoma by deep sequencing.

Authors:  Shu-Jen Chen; Gian-Hung Chen; Yi-Hsuan Chen; Cheng-Yuan Liu; Kai-Ping Chang; Yu-Sun Chang; Hua-Chien Chen
Journal:  PLoS One       Date:  2010-09-20       Impact factor: 3.240

8.  An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells.

Authors:  Pavel A Nikitin; Christopher M Yan; Eleonora Forte; Alessio Bocedi; Jason P Tourigny; Robert E White; Martin J Allday; Amee Patel; Sandeep S Dave; William Kim; Katherine Hu; Jing Guo; David Tainter; Elena Rusyn; Micah A Luftig
Journal:  Cell Host Microbe       Date:  2010-12-16       Impact factor: 21.023

9.  Complexities associated with expression of Epstein-Barr virus (EBV) lytic origins of DNA replication.

Authors:  Shao-An Xue; Beverly E Griffin
Journal:  Nucleic Acids Res       Date:  2007-05-03       Impact factor: 16.971

10.  Nasopharyngeal carcinoma incidence and mortality in China in 2009.

Authors:  Zhi-Jian Xu; Rong-Shou Zheng; Si-Wei Zhang; Xiao-Nong Zou; Wan-Qing Chen
Journal:  Chin J Cancer       Date:  2013-07-18
View more
  27 in total

1.  Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan.

Authors:  Allan Hildesheim; Denise L Doolan; Anna E Coghill; Ruth M Pfeiffer; Carla Proietti; Wan-Lun Hsu; Yin-Chu Chien; Lea Lekieffre; Lutz Krause; Andy Teng; Jocelyn Pablo; Kelly J Yu; Pei-Jen Lou; Cheng-Ping Wang; Zhiwei Liu; Chien-Jen Chen; Jaap Middeldorp; Jason Mulvenna; Jeff Bethony
Journal:  Clin Cancer Res       Date:  2018-01-04       Impact factor: 12.531

2.  Nasopharyngeal carcinoma super-enhancer-driven ETV6 correlates with prognosis.

Authors:  Liangru Ke; Hufeng Zhou; Chong Wang; Geng Xiong; Yanqun Xiang; Yihong Ling; Abdelmajid Khabir; George S Tsao; Yixin Zeng; Musheng Zeng; Pierre Busson; Elliott Kieff; Xiang Guo; Bo Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-22       Impact factor: 11.205

3.  Identification of ARKL1 as a Negative Regulator of Epstein-Barr Virus Reactivation.

Authors:  Umama Z Siddiqi; Anup S Vaidya; Xinliu Li; Edyta Marcon; Sai Wah Tsao; Jack Greenblatt; Lori Frappier
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

4.  The mTOR inhibitor manassantin B reveals a crucial role of mTORC2 signaling in Epstein-Barr virus reactivation.

Authors:  Qian Wang; Nannan Zhu; Jiayuan Hu; Yan Wang; Jun Xu; Qiong Gu; Paul M Lieberman; Yan Yuan
Journal:  J Biol Chem       Date:  2020-04-20       Impact factor: 5.157

5.  Analysis of Epstein-Barr Virus Genomes and Expression Profiles in Gastric Adenocarcinoma.

Authors:  Lori Frappier; Vincent Ferretti; Ivan Borozan; Marc Zapatka
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

6.  T cell epitope screening of Epstein-Barr virus fusion protein gB.

Authors:  Haiwen Chen; Xiao Zhang; Shanshan Zhang; Xiaobing Duan; Tong Xiang; Xiang Zhou; Wanlin Zhang; Xinyu Zhang; Qisheng Feng; Yinfeng Kang; Jiangping Li; Lan Deng; Liang Wang; Xing Lv; Musheng Zeng; Yi-Xin Zeng; Miao Xu
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

7.  Detection and characterization of latency stage of EBV and histopathological analysis of prostatic adenocarcinoma tissues.

Authors:  Khalid Ahmed; Alisalman Sheikh; Saira Fatima; Ghulam Haider; Kulsoom Ghias; Farhat Abbas; Nouman Mughal; Syed Hani Abidi
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

8.  A Screen for Epstein-Barr Virus Proteins That Inhibit the DNA Damage Response Reveals a Novel Histone Binding Protein.

Authors:  Ting-Hin Ho; Justine Sitz; Qingtang Shen; Ariane Leblanc-Lacroix; Eric I Campos; Ivan Borozan; Edyta Marcon; Jack Greenblatt; Amelie Fradet-Turcotte; Dong-Yan Jin; Lori Frappier
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

Review 9.  Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas.

Authors:  Helen E Heslop; Sandhya Sharma; Cliona M Rooney
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544

Review 10.  Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer.

Authors:  Ramon Yarza; Mateo Bover; Maria Teresa Agulló-Ortuño; Lara Carmen Iglesias-Docampo
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.